Brenda Shoup, MD
Gynecologic Oncology · Merriam, KSNPI 1043266620
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $493 and has fallen 67.1% since, to $162 in 2025.
Across 72 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$196
- AbbVie$184
- Clovis Oncology, Inc.$150
- AstraZeneca$115
- Daiichi Sankyo Inc.$84
- Merck$68
- plus $497 from 18 others
What the payments were for
- Food & beverage$1,22895%
- Education$655%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 10 | $196 |
| AbbVie | 13 | $184 |
| Clovis Oncology, Inc. | 11 | $150 |
| AstraZeneca | 3 | $115 |
| Daiichi Sankyo Inc. | 5 | $84 |
| Merck | 5 | $68 |
| Tesaro, Inc. | 3 | $61 |
| Amgen | 3 | $52 |
| Integra Lifesciences Corporation | 1 | $52 |
| Intuitive Surgical | 2 | $48 |
| Sanofi | 2 | $42 |
| Incyte Corporation | 2 | $33 |
| Medtronic | 1 | $24 |
| Puma Biotechnology, Inc. | 1 | $24 |
| Sobi, Inc | 1 | $22 |
| BD | 1 | $20 |
| Seagen Inc. | 1 | $19 |
| Tersera Therapeutics LLC | 1 | $16 |
| Davol Inc. | 1 | $16 |
| Novartis | 1 | $16 |
| Angiodynamics, Inc. | 1 | $15 |
| Bristol Myers Squibb | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $11 |
How this compares
Too few gynecologic oncology providers in Kansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tolterodine Tartrate ErTolterodine Tartrate | 12 | $408 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 29 | $161 |
| Ibuprofen | 35 | $93 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Merriam
- Sara LangeMerriam$3K
- Alaa ElbendaryOverland Park$5K
- Lindsay HasselwanderWestwood$3K
- Lowell ByersShawnee Mission$2K
- Jacqueline MorganWichita$2K
- Yasmin AbedinKansas City$1K
- James DelmoreWichita$852
- Michelle DudzinskiShawnee Mission$832
- Rana AlianiKansas City$194
- Thomas ChavezKansas City$119
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.